Home » European Medicines Agency Reviews Risk of Suicidal Thoughts and Self-Harm Linked to GLP-1 Receptor Agonists

European Medicines Agency Reviews Risk of Suicidal Thoughts and Self-Harm Linked to GLP-1 Receptor Agonists

by admin

Title: European Medicines Agency Investigating Potential Link between GLP-1 Receptor Agonists and Suicidal Thoughts

In a recent development, the European Medicines Agency (EMA) has revealed that its Committee for Safety is currently reviewing data concerning the risk of suicidal thoughts and thoughts of self-harm associated with GLP-1 receptor agonists. These medications are commonly used for weight loss as well as the treatment of type 2 diabetes.

While issuing a note urging caution, the EMA highlighted that it is yet to ascertain whether the reported cases of such thoughts are directly linked to the medications themselves, the underlying conditions of the patients, or other factors.

This review was initiated by the Icelandic drug agency, prompted by reports of suicidal thoughts and self-harm in individuals using liraglutide and semaglutide-based drugs. As part of the analysis, approximately 150 reports have been retrieved and subjected to thorough examination.

Providing further insight, the EMA explained that liraglutide and semaglutide are widely used medications, with more than 20 million patients being exposed to these drugs annually. The specific products under investigation are marketed under the names of Saxenda, Wegovy, and Ozempic.

According to the EMA, Saxenda and Wegovy are authorized for weight management in obese or overweight individuals. On the other hand, Ozempic is approved for the treatment of adults with insufficiently controlled type 2 diabetes but has been used off-label for weight loss purposes.

At present, no restrictions have been imposed on the prescription and utilization of these products. The EMA clarified that the presence of a signal does not necessarily imply that a medicine is responsible for the reported adverse events.

See also  Are you affected? Five symptoms suggest post-holiday syndrome

Nevertheless, the regulatory agency has recommended that both patients and healthcare providers adhere to the approved product information when using GLP-1 receptor agonists. Additionally, they are encouraged to promptly report any suspected side effects to the relevant authorities.

The conclusions of this investigation are anticipated to be announced by November of this year.

To read the full article, visit ANSA.it.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy